Eli Lilly agreed to buy Kelonia Therapeutics for up to $7 billion, aiming to broaden its in-vivo CAR-T strategy with a one-time intravenous therapy in multiple myeloma. The deal includes a $3.25 billion upfront payment and additional milestone-based consideration tied to clinical, regulatory, and commercial outcomes, with closing expected in the second half of 2026. Kelonia’s lead candidate, KLN-1010, is an in-vivo lentiviral CAR-T approach designed to generate anti-BCMA CAR T cells inside the patient. Lilly framed the program as a way to reduce the manufacturing and access barriers of ex-vivo CAR-T and to potentially extend in-vivo CAR-T beyond hematology over time. Industry takeaways center on scale and operational convenience: in-vivo CAR-T could shift where and how CAR-T is delivered, while also changing the competitive landscape for next-generation cell therapies. Kelonia’s earlier FDA clearance for an IND and initial clinical signals have helped make the platform acquisition attractive to a major pharma buyer looking to diversify beyond traditional oncology franchises.